NeuroSigma, which develops electrical devices used to treat drug-resistant epilepsy and depression, announced terms for its IPO on Monday. The Los Angeles, CA-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, NeuroSigma would command a fully diluted market value of $204 million.
The company is in pivotal trials to have its bioelectronic products approved in the US, and has received marketing approval as an adjunctive therapy for adults in Australia, Canada and the EU.
Help employers find you! Check out all the jobs and post your resume.
The company is in pivotal trials to have its bioelectronic products approved in the US, and has received marketing approval as an adjunctive therapy for adults in Australia, Canada and the EU.
Help employers find you! Check out all the jobs and post your resume.
